This study is testing a drug called AL8326 for people with small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), or renal cell carcinoma (RCC, a type of kidney cancer) that has returned or spread, and who have already finished their first treatment. AL8326 is a type of medicine called a tyrosine kinase inhibitor, which works by blocking certain signals that help cancer cells grow. The study aims to find the best dose of AL8326 and see how well it works. You might be able to join if you are 18 or older, have one of these cancer types confirmed by a doctor, and have at least one measurable tumor. The study is currently unclear on its recruitment status, but it plans to enroll 80 participants.

Study design

This is a Phase 2 interventional study designed to find the optimal biological dose of AL8326. It involves randomizing participants to different dosing groups.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will evaluate optimal biological dose and objective response rates for 12 months, and for NSCLC and RCC, objective response rates will be evaluated for 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.